Diagnosing and Treating Gout: A Review to Aid Primary Care Physicians

References

• . Hanly JG, Skedgel C, Sketris I, . Gout in the elderly–a population health study. J Rheumatol. 2009;36(4):822–830
   PubMed Web of Science ®Google Scholar
• . Baer PA, Tenenbaum J, Fam AG, Little H. Coexistent septic and crystal arthritis. Report of four cases and literature review. J Rheumatol. 1986;13(3):604–607
   PubMed Web of Science ®Google Scholar
• . Grahame R, Scott JT. Clinical survey of 354 patients with gout. Ann Rheum Dis. 1970;29(5):461–468
   PubMed Web of Science ®Google Scholar
• . Reginato AJ, Schumacher HR Jr. Crystal-associated arthropathies. Clin Geriatr Med. 1988;4(2):295–322
   PubMedGoogle Scholar
• . Schlesinger N. Response to application of ice may help differentiate between gouty arthritis and other inflammatory arthritidies. J Clin Rheumatol. 2006;12(6):275–276
   PubMed Web of Science ®Google Scholar
• . Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895–900
   PubMed Web of Science ®Google Scholar
• . Zhang W, Doherty M, Pascual E, ; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis. 2006;65(10):1312–1324
   PubMed Web of Science ®Google Scholar
• . Wolfe F, Cathy MA. The misdiagnosis of gout and hyperuricemia. J Rheumatol. 1991;18(8):1232–1234
   PubMed Web of Science ®Google Scholar
• . Schlesinger N, Watson DJ, Norquist JM. Serum urate during acute gout. J Rheumatol. 2009;36(6):1287–1289
   PubMed Web of Science ®Google Scholar
• . Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drug. 2004;64(21):2399–2416
   PubMed Web of Science ®Google Scholar
• . Dessein PH, Shipton AE, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum and lipoprotein levels in gout: a pilot study. Ann Rheum Dis. 2000;59(7):539–543
   PubMed Web of Science ®Google Scholar
• . Schlesinger N, Baker DG, Beutler AM, . Local ice therapy during bouts of acute gouty arthritis. J Rheumatol. 2002;29(2):331–334
   PubMed Web of Science ®Google Scholar
• . Petersel D, Schlesinger N. Treatment of acute gout in hospitalized patients. J Rheumatol. 2007;34(7):1566–1568
   PubMed Web of Science ®Google Scholar
• . Schlesinger N, Moore DF, Sun JD, Schumacher HR. A survey of current evaluation and treatment of gout. J Rheumatol. 2006;33(10):2050–2052
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. Colcrys http://www.fda.gov/Drugs/Drug Safety/Postmarket Drug Safety Information
   Google Scholar
• . Schlesinger N. Overview of the management of acute gout and the role of adrenocorticotropic hormone. Leading article. Drugs. 2008;68(4):407–415
   PubMed Web of Science ®Google Scholar
• . Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomized equivalence trial. Lancet. 2008;371(9627):1854–1860
   PubMed Web of Science ®Google Scholar
• . Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321–325
   PubMed Web of Science ®Google Scholar
• . Li-Yu J, Clayburne G, Sieck M, . Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol. 2001;28(3):577–580
   PubMed Web of Science ®Google Scholar
• . Perez-Ruiz F, Calabozo M, Pijoan SI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Care Res. 2002;47(4):356–360
   Web of Science ®Google Scholar
• . Yamanaka H, Togashi R, Hakoda M, . Optimal range of serum urate concentrations to minimize risk of gouty attacks during antihyperuricemic treatment. Adv Exp Med Biol. 1998;431:13–18
   PubMed Web of Science ®Google Scholar
• . van Lieshout-Zuidema MF, Breedveld FC. Withdrawal of long-term antihyperuricemic therapy in tophaceous gout. J Rheumatol. 1993;20(8):1383–1385
   PubMed Web of Science ®Google Scholar
• . Bull PW, Scott JT. Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol. 1989;16(9);1246–1248
   PubMed Web of Science ®Google Scholar
• . Sarawate CA, Brewer KK, Yang W, . Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81(7):925–934
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index
   Google Scholar
• . Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, García-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998;57(9):545–549
   PubMed Web of Science ®Google Scholar
• . Becker MA, Schumacher HR Jr, Wortmann RL, . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–2461
   PubMed Web of Science ®Google Scholar
• . Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial. 2007;20(5):391–395
   PubMed Web of Science ®Google Scholar
• . Halevy S, Ghislain PD, Mockenhaupt M, ; EuroSCAR Study Group. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58(1):25–32
   PubMed Web of Science ®Google Scholar
• . Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76(1):47–56
   PubMed Web of Science ®Google Scholar
• . Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33(8):646–650
   Web of Science ®Google Scholar
• . Emmerson BT. The management of gout. N Engl J Med. 1996;334(7):445–451
   PubMed Web of Science ®Google Scholar
• . Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005;165(7):742–748
   PubMed Web of Science ®Google Scholar